Skip to content
Peptissima Research Centre

Research. Evidence. Understanding.

Explore peer-reviewed peptide research, scientific publications and emerging developments from trusted journals, manufacturers and recognised institutions. Our Research Centre is designed to help researchers and informed audiences navigate one of the fastest-evolving areas of biological science.

Explore research library View Research Products
Research focus

Explore Research Areas

The fields below describe where published peptide research has been directed. They are listed for educational context and in no order of preference.

Metabolic Research

  • GLP-1
  • GIP
  • Glucagon
  • Triple agonists
  • Metabolic signalling
  • Energy regulation

Tissue Repair

  • BPC-157
  • TB-500
  • Musculoskeletal biology
  • Angiogenesis
  • Connective tissue

Cellular Biology

  • GHK-Cu
  • Copper peptides
  • Collagen signalling
  • Skin biology
  • Extracellular matrix

Emerging Science

  • Novel peptides
  • Drug discovery
  • Delivery systems
  • Longevity research
  • Precision medicine

These are fields of scientific study. They describe where laboratory and clinical research has been conducted, and are not descriptions of the use, purpose or effect of any product supplied by Peptissima Health. No clinical benefit is implied.

Research spotlight

Retatrutide

Triple agonist of GLP-1, GIP and glucagon receptors

Research summary

Retatrutide is an investigational peptide examined in published clinical research for its simultaneous interaction with three metabolic receptors. Findings to date are drawn from peer-reviewed trials and remain subject to ongoing review.

Mechanism

Investigated for combined activity at the GLP-1, GIP and glucagon receptors. Published research has examined the relationship between this combination and appetite signalling, glucose regulation and energy balance.

Current scientific interest

Interest centres on whether engaging three receptor pathways together produces a different research profile from single and dual receptor peptides. Independent groups continue to publish on mechanism, tolerability and study design.

Read research overview

Research Landscape

Compound Human evidence Research stage Literature volume
Retatrutide Extensive Phase III High
GHK-Cu Moderate Experimental High
BPC-157 Limited Experimental Moderate
TB-500 Limited Experimental Moderate

Overview based on publicly available scientific literature and subject to change as new evidence emerges. It describes the volume and stage of published research only, and is not an assessment of safety, quality or efficacy.

Development status

Clinical Development Overview

Where each compound currently sits in the published research record. Positions describe the stage of investigation reported in the scientific literature.

Retatrutide

Triple agonist

Late-stage clinical development

BPC-157

Tissue repair research

Early human investigation

TB-500

Tissue repair research

Preclinical and early research

GHK-Cu

Copper peptide research

Clinical and laboratory research

Positions reflect the stage of investigation described in published literature at the time of writing. No approval dates, projected timelines or predictions of outcome are shown or implied, and nothing here indicates that a compound is approved for human use.

Research library

Research Library

A curated reading list of peer-reviewed publications held by recognised journals and indexed on PubMed. Every entry opens the original record on the publisher's or index's own site.

More scientific resources

These publications are the work of independent researchers and are listed for educational reference only. Peptissima Health does not conduct original research, publish scientific data or hold any affiliation with the journals, indexes or institutions named. Listing a publication is not an endorsement of its findings, and nothing here constitutes medical advice.

Featured research insight

Why Triple Agonists Are Being Studied

One publication, read in the context of the field around it.

Earlier metabolic peptides were investigated at a single receptor. The publication below reports a phase 2 trial of a peptide examined for combined activity at three: GLP-1, GIP and glucagon.

Researchers are examining whether engaging several metabolic pathways together produces a different research profile from single and dual receptor peptides. The question remains open, and the trial record is early.

Read the publication
The publication
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM et al. The New England Journal of Medicine · 2023

The commentary above is educational summary written by Peptissima Health. It is not the conclusion of the authors, is not medical advice, and does not describe the use, purpose or effect of any product supplied by Peptissima Health.

Peptide intelligence

Our Research Intelligence Covers

What we read, monitor and summarise for this Research Centre. Peptissima Health curates published material from these sources — it does not generate it.

  • Peer-reviewed publications
  • Clinical studies
  • Regulatory updates
  • Conference highlights
  • Manufacturing standards
  • Safety developments
  • Patent activity
  • Academic collaborations
  • Industry trends
  • Scientific reviews
References & resources

Trusted Scientific Sources

  • PubMed
  • Nature
  • Science
  • The Lancet
  • NEJM
  • JAMA
  • BMJ
  • Cell
  • FDA
  • EMA
  • MHRA

The journals, indexes and regulatory bodies named above are the sources Peptissima Health reads. All names and marks remain the property of their respective owners. Peptissima Health is not affiliated with, endorsed by, accredited by or connected to any of them, and none of them has reviewed or approved this website or any product supplied through it.

Responsible Scientific Communication

Peptissima Health curates scientific literature from recognised journals, manufacturers and regulatory sources so that readers can form an informed scientific understanding. Information provided throughout this Research Centre is educational in nature and should not be interpreted as medical advice or evidence of product efficacy.

Products supplied through Peptissima Health are intended solely for legitimate laboratory research where permitted by applicable law and regulations. They are not approved for human consumption, and are not intended to diagnose, treat, cure or prevent any disease.

All products supplied by Peptissima Health are intended solely for legitimate laboratory research use where permitted by law. They are not medicines, medical devices, foods, cosmetics or dietary supplements, and are not intended for human consumption or for the diagnosis, treatment, cure or prevention of any disease. Product information is published for scientific and educational purposes only and does not constitute medical advice.

Statements on this site describe what published research and manufacturer documentation record. They are not claims about outcomes and must not be read as such. Purchasers are responsible for confirming the legal status of any compound in their own jurisdiction.